Home › Companies › Vanda Pharmaceuticals Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Vanda Pharmaceuticals Inc.’s Form 8-K, filed 2026-06-05 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Explore Vanda Pharmaceuticals Inc. in the interactive database Compare manager voting policies
These tallies are Vanda Pharmaceuticals Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-05 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Richard W. Dugan | 33,029,049 | 5,417,322 | 46,718 | -- | 10,016,817 | Majority: yes |
| Elect Director: Charles C. Duncan, Ph.D. | 35,780,031 | 2,664,889 | 48,169 | -- | 10,016,817 | Majority: yes |
| Elect Director: Anne Sempowski Ward | 33,897,782 | 4,543,488 | 51,819 | -- | 10,016,817 | Majority: yes |
| Proposal 2: Ratification of Selection of PricewaterhouseCoopers LLP | 48,103,698 | 340,513 | 65,695 | -- | -- | Majority: yes |
| Proposal 3: Advisory Vote on Named Executive Officer Compensation | 35,242,659 | 3,167,243 | 83,187 | -- | 10,016,817 | Majority: yes |
| Proposal 4: Amendment to the Company's 2016 Plan | 31,729,991 | 6,685,078 | 78,020 | -- | 10,016,817 | Majority: yes |
Source: Vanda Pharmaceuticals Inc., Form 8-K, filed with the SEC on 2026-06-05 — read the filing on EDGAR.
Each item below shows how the 181 asset managers that disclosed a Vanda Pharmaceuticals Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Vanda Pharmaceuticals Inc.’s own tally for this item (“Proposal 3: Advisory Vote on Named Executive Officer Compensation”): 35,242,659 for, 3,167,243 against, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,135,062 outstanding shares: 59% for, 5% against (64% of the company cast a for/against vote).
The 177 asset managers below cast 97% of the shares they voted on this item FOR (33,300,426 for, 884,312 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 6,184,918 | 0 | 0 | 0 | For |
| Vanguard | 3,998,651 | 12 | 0 | 0 | For |
| State Street | 2,972,076 | 4,437 | 0 | 0 | For |
| Renaissance | 2,497,122 | 0 | 0 | 0 | For |
| AIGH Capital Management LLC | 1,861,177 | 0 | 0 | 0 | For |
| Fidelity | 1,564,711 | 0 | 0 | 0 | For |
| AQR | 1,468,396 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,456,863 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 1,315,435 | 0 | 0 | 0 | For |
| Charles Schwab | 1,212,636 | 0 | 0 | 0 | For |
| Federated Hermes | 1,082,055 | 7,779 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 689,427 | 0 | 0 | 0 | For |
| Dimensional | 677,523 | 0 | 0 | 0 | For |
| Northern Trust | 538,493 | 2,901 | 0 | 0 | For |
| Two Sigma | 430,102 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 385,556 | 0 | 0 | 0 | For |
| Citadel | 339,685 | 0 | 0 | 0 | For |
| American Century | 0 | 298,510 | 0 | 0 | Against |
| Goldman Sachs | 261,146 | 0 | 0 | 0 | For |
| Monaco Asset Management SAM | 0 | 241,286 | 0 | 0 | Against |
| Invesco | 238,889 | 0 | 0 | 0 | For |
| Nationwide | 238,810 | 0 | 0 | 0 | For |
| KENNEDY CAPITAL MANAGEMENT LLC | 216,693 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 195,051 | 0 | 0 | 0 | For |
| JPMorgan | 185,923 | 0 | 0 | 0 | For |
Showing the 25 largest of 177 asset managers. See all 177 in the interactive database.
Combines 3 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Vanda Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Richard W. Dugan”): 33,029,049 for, 5,417,322 against, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,135,062 outstanding shares: 54.9% for, 9% against (64% of the company cast a for/against vote).
The 60 asset managers below cast 95% of the shares they voted on this item FOR (13,114,815 for, 688,767 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,528,674 | 8,221 | 0 | 0 | For |
| BlackRock | 2,947,811 | 0 | 0 | 0 | For |
| State Street | 1,881,199 | 2,495 | 0 | 0 | For |
| Fidelity | 1,484,543 | 0 | 0 | 0 | For |
| Charles Schwab | 606,265 | 0 | 0 | 0 | For |
| Federated Hermes | 529,083 | 0 | 0 | 0 | For |
| Dimensional | 0 | 446,261 | 0 | 0 | Against |
| Nationwide | 238,810 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 195,051 | 0 | 0 | 0 | For |
| JPMorgan | 185,923 | 0 | 0 | 0 | For |
| American Century | 149,191 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 139,780 | 0 | 0 | Against |
| Equitable | 88,647 | 47,550 | 0 | 0 | For |
| TIAA | 116,066 | 0 | 0 | 0 | For |
| Goldman Sachs | 101,010 | 0 | 0 | 0 | For |
| Invesco | 95,444 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 93,404 | 0 | 0 | 0 | For |
| MFS | 83,716 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 63,292 | 0 | 0 | 0 | For |
| Brighthouse | 58,619 | 0 | 3,390 | 0 | For |
| AIG/SunAmerica | 60,619 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 52,295 | 0 | 0 | 0 | For |
| ProShares | 50,669 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 48,116 | 0 | 0 | 0 | For |
| Lincoln Financial | 37,981 | 8,874 | 0 | 0 | For |
Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.
Combines 4 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Vanda Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Charles C. Duncan, Ph.D.”): 35,780,031 for, 2,664,889 against, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,135,062 outstanding shares: 59% for, 4% against (64% of the company cast a for/against vote).
The 60 asset managers below cast 99.9% of the shares they voted on this item FOR (13,803,051 for, 531 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,536,885 | 10 | 0 | 0 | For |
| BlackRock | 2,947,811 | 0 | 0 | 0 | For |
| State Street | 1,883,173 | 521 | 0 | 0 | For |
| Fidelity | 1,484,543 | 0 | 0 | 0 | For |
| Charles Schwab | 606,265 | 0 | 0 | 0 | For |
| Federated Hermes | 529,083 | 0 | 0 | 0 | For |
| Dimensional | 446,261 | 0 | 0 | 0 | For |
| Nationwide | 238,810 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 195,051 | 0 | 0 | 0 | For |
| JPMorgan | 185,923 | 0 | 0 | 0 | For |
| American Century | 149,191 | 0 | 0 | 0 | For |
| Northern Trust | 139,780 | 0 | 0 | 0 | For |
| Equitable | 136,197 | 0 | 0 | 0 | For |
| TIAA | 116,066 | 0 | 0 | 0 | For |
| Goldman Sachs | 101,010 | 0 | 0 | 0 | For |
| Invesco | 95,444 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 93,404 | 0 | 0 | 0 | For |
| MFS | 83,716 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 63,292 | 0 | 0 | 0 | For |
| Brighthouse | 58,619 | 0 | 3,390 | 0 | For |
| AIG/SunAmerica | 60,619 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 52,295 | 0 | 0 | 0 | For |
| ProShares | 50,669 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 48,116 | 0 | 0 | 0 | For |
| Lincoln Financial | 46,855 | 0 | 0 | 0 | For |
Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.
Combines 3 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Vanda Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Anne Sempowski Ward”): 33,897,782 for, 4,543,488 against, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,135,062 outstanding shares: 56% for, 8% against (64% of the company cast a for/against vote).
The 60 asset managers below cast 96% of the shares they voted on this item FOR (13,257,355 for, 546,227 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,531,359 | 5,536 | 0 | 0 | For |
| BlackRock | 2,947,811 | 0 | 0 | 0 | For |
| State Street | 1,881,273 | 2,421 | 0 | 0 | For |
| Fidelity | 1,484,543 | 0 | 0 | 0 | For |
| Charles Schwab | 606,265 | 0 | 0 | 0 | For |
| Federated Hermes | 529,083 | 0 | 0 | 0 | For |
| Dimensional | 0 | 446,261 | 0 | 0 | Against |
| Nationwide | 238,810 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 195,051 | 0 | 0 | 0 | For |
| JPMorgan | 185,923 | 0 | 0 | 0 | For |
| American Century | 149,191 | 0 | 0 | 0 | For |
| Northern Trust | 139,780 | 0 | 0 | 0 | For |
| Equitable | 88,647 | 47,550 | 0 | 0 | For |
| TIAA | 116,066 | 0 | 0 | 0 | For |
| Goldman Sachs | 101,010 | 0 | 0 | 0 | For |
| Invesco | 95,444 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 93,404 | 0 | 0 | 0 | For |
| MFS | 83,716 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 63,292 | 0 | 0 | 0 | For |
| Brighthouse | 58,619 | 0 | 3,390 | 0 | For |
| AIG/SunAmerica | 60,619 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 52,295 | 0 | 0 | 0 | For |
| ProShares | 50,669 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 48,116 | 0 | 0 | 0 | For |
| Lincoln Financial | 37,981 | 8,874 | 0 | 0 | For |
Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.2% Majority: yes · of votes cast
Vanda Pharmaceuticals Inc.’s own tally for this item (“Proposal 2: Ratification of Selection of PricewaterhouseCoopers LLP”): 48,103,698 for, 340,513 against, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,135,062 outstanding shares: 80% for, 0.6% against (81% of the company cast a for/against vote).
The 60 asset managers below cast 99.9% of the shares they voted on this item FOR (13,800,525 for, 3,057 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,534,210 | 2,685 | 0 | 0 | For |
| BlackRock | 2,947,811 | 0 | 0 | 0 | For |
| State Street | 1,883,620 | 74 | 0 | 0 | For |
| Fidelity | 1,484,543 | 0 | 0 | 0 | For |
| Charles Schwab | 606,265 | 0 | 0 | 0 | For |
| Federated Hermes | 529,083 | 0 | 0 | 0 | For |
| Dimensional | 446,261 | 0 | 0 | 0 | For |
| Nationwide | 238,810 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 195,051 | 0 | 0 | 0 | For |
| JPMorgan | 185,923 | 0 | 0 | 0 | For |
| American Century | 149,191 | 0 | 0 | 0 | For |
| Northern Trust | 139,780 | 0 | 0 | 0 | For |
| Equitable | 136,197 | 0 | 0 | 0 | For |
| TIAA | 116,066 | 0 | 0 | 0 | For |
| Goldman Sachs | 101,010 | 0 | 0 | 0 | For |
| Invesco | 95,444 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 93,404 | 0 | 0 | 0 | For |
| MFS | 83,716 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 63,292 | 0 | 0 | 0 | For |
| Brighthouse | 58,619 | 0 | 3,390 | 0 | For |
| AIG/SunAmerica | 60,619 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 52,295 | 0 | 0 | 0 | For |
| ProShares | 50,669 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 48,116 | 0 | 0 | 0 | For |
| Lincoln Financial | 46,855 | 0 | 0 | 0 | For |
Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.
Combines 2 wordings of this item as funds reported it.
83% Majority: yes · of votes cast
Vanda Pharmaceuticals Inc.’s own tally for this item (“Proposal 4: Amendment to the Company's 2016 Plan”): 31,729,991 for, 6,685,078 against, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,135,062 outstanding shares: 52.8% for, 11% against (64% of the company cast a for/against vote).
The 60 asset managers below cast 81% of the shares they voted on this item FOR (11,198,759 for, 2,604,822 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,531,350 | 5,544 | 0 | 0 | For |
| BlackRock | 2,947,811 | 0 | 0 | 0 | For |
| State Street | 3,501 | 1,880,193 | 0 | 0 | Against |
| Fidelity | 1,484,543 | 0 | 0 | 0 | For |
| Charles Schwab | 606,265 | 0 | 0 | 0 | For |
| Federated Hermes | 0 | 529,083 | 0 | 0 | Against |
| Dimensional | 446,261 | 0 | 0 | 0 | For |
| Nationwide | 238,810 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 195,051 | 0 | 0 | 0 | For |
| JPMorgan | 185,923 | 0 | 0 | 0 | For |
| American Century | 0 | 149,191 | 0 | 0 | Against |
| Northern Trust | 139,780 | 0 | 0 | 0 | For |
| Equitable | 136,197 | 0 | 0 | 0 | For |
| TIAA | 116,066 | 0 | 0 | 0 | For |
| Goldman Sachs | 101,010 | 0 | 0 | 0 | For |
| Invesco | 95,444 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 93,404 | 0 | 0 | 0 | For |
| MFS | 83,716 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 63,292 | 0 | 0 | 0 | For |
| Brighthouse | 58,619 | 0 | 3,390 | 0 | For |
| AIG/SunAmerica | 60,619 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 52,295 | 0 | 0 | 0 | For |
| ProShares | 50,669 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 48,116 | 0 | 0 | 0 | For |
| Lincoln Financial | 8,874 | 37,981 | 0 | 0 | Against |
Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.
Ranked by the number of Vanda Pharmaceuticals Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 60,135,062 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 10.29% |
| 2 | Vanguard | 6.65% |
| 3 | State Street | 4.95% |
| 4 | Renaissance | 4.15% |
| 5 | AIGH Capital Management LLC | 3.09% |
| 6 | Fidelity | 2.60% |
| 7 | AQR | 2.44% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.42% |
| 9 | ACADIAN ASSET MANAGEMENT LLC | 2.19% |
| 10 | Charles Schwab | 2.02% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock, Inc. | 7.81% | DEF14A |
| Vanguard Group | 6.21% | 13F |
| Renaissance Technologies LLC | 6.12% | DEF14A |
| Millennium Management LLC | 5.61% | 13G |
| Mihael H. Polymeropoulos, M.D. | 5.09% | DEF14A |
| State Street | 5.01% | 13F |
| BlackRock Portfolio Management LLC | 4.17% | 13G |
| Dimensional Fund Advisors | 2.95% | 13F |
| Geode Capital | 2.40% | 13F |
| Two Sigma | 2.33% | 13F |
Percentages above are of 60,135,062 shares outstanding, as reported by Vanda Pharmaceuticals Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Vanda Pharmaceuticals Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At Vanda Pharmaceuticals Inc.'s shareholder meeting held 2026-06-04, in the 2025-2026 proxy season, 181 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 1,266 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the Company's named executive officer compensation. — FOR was 92% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Vanda Pharmaceuticals Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-05.
Vanda Pharmaceuticals Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).